Company Profiles

driven by the PitchBook Platform

Angiochem

Description

Developer of drugs designed to treat brain diseases and brain-related disorders. The company's drugs are use for the treatment of brain cancer, cancer metastases and neurodegenerative and metabolic diseases, enabling patients to start their treatment more quickly and result in a higher likelihood of a successful treatment.

2003

Founded

PRIVATE

Status

11-50

Employees

Series B

Latest Deal Type

$14M

Latest Deal Amount

$35.8M

Total Amount Raised

Description

Developer of drugs designed to treat brain diseases and brain-related disorders. The company's drugs are use for the treatment of brain cancer, cancer metastases and neurodegenerative and metabolic diseases, enabling patients to start their treatment more quickly and result in a higher likelihood of a successful treatment.

Website:

www.angiochem.com

Ownership Status

Privately Held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Discovery

Other Industries

Pharmaceuticals
Biotechnology

Primary Office

201 President-Kennedy Avenue Suite PK-2880 Montreal, Quebec H2X 3Y7Canada +1 (514) 788-7800
    Request a free trial to the PitchBook Platform
    You're viewing a free company profile from the PitchBook Platform. To explore Angiochem's full profile, request a free trial.

    Angiochem Valuation and Funding

    Request access
    Deal TypeDateAmountRaised to DatePost-ValStatusStage

    Angiochem Investors (4)

    Request access
    Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
    Seat
    Contact
    Info
    BDC Healthcare Venture FundVenture CapitalMinority000 0000000 0000
    Individual InvestorAngel (individual)Minority000 0000000 0000
    ValeoCorporationMinority000 0000000 0000
    VIMAC VenturesVenture CapitalMinority000 0000000 0000
    BDC Healthcare Venture Fund Venture Capital
    Individual Investor Angel (individual)
    Valeo Corporation
    VIMAC Ventures Venture Capital

    Angiochem Executive Team (7)

    NameTitleBoard
    Seat
    Contact
    Info
    Jean-Paul Castaigne MDPresident, Chief Executive Officer & Board Member
    Jean Lachowicz Ph.DChief Scientific Officer
    Catherine GagnonDirector, Corporate Development
    Michel Demeule Ph.DDirector, Research
    Richard BeliveauScientific Founder
    Jean-Paul Castaigne MD President, Chief Executive Officer & Board Member
    Jean Lachowicz Ph.D Chief Scientific Officer
    Catherine Gagnon Director, Corporate Development
    Michel Demeule Ph.D Director, Research
    Richard Beliveau Scientific Founder

    Angiochem Board Members (5)

    NameRepresentingRoleSinceContact
    Info
    Jean-François PariseauBDC Healthcare Venture FundPartner000 0000
    John HussAngiochemBoard Member000 0000
    Martin Godbout Ph.DSelfBoard Member000 0000
    Robert BlainSelfBoard Member000 0000
    Sena Biswas Ph.DVIMAC VenturesManaging Director, Life Sciences000 0000
    Jean-François Pariseau Partner BDC Healthcare Venture Fund
    John Huss Board Member Angiochem
    Martin Godbout Ph.D Board Member Self
    Robert Blain Board Member Self
    Sena Biswas Ph.D Managing Director, Life Sciences VIMAC Ventures
    Request full access to PitchBook